Clinical trials: Cushing Disease
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Cushings Disease, Cushing Disease
Safety and Efficacy of LCI699 in Cushing's Disease Patients
This exploratory study is a proof of concept study to determine whether LCI699 can safely reduce the level of urinary free cortisol in patients with Cushing's disease.
- Trial name
- NCT01331239
- Testing
- LCI699
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Endogenous Cushing's Syndrome
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
This is a double-blind, randomized, placebo-controlled withdrawal and rescue/restoration study in subjects with endogenous Cushing's Syndrome (CS) previously treated with single-arm, open-label levoketoconazole that will assess…
- Trial name
- NCT03277690
- Testing
- Levoketoconazole
- Where
- 45 sites in United States, Bulgaria and 10 more
- Volunteers
- 84 people
- Sponsor
- Cortendo AB
Cushing's Syndrome, Ectopic Corticotropin Syndrome
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
The study aim was to investigate the efficacy and safety of Osilodrostat in patients with Cushing's syndrome due to causes other than Cushing's disease in Japan.
- Conditions
- Cushing's Syndrome, Ectopic Corticotropin Syndrome, Adrenal Adenoma, Adrenal Carcinoma
- Trial name
- NCT02468193
- Testing
- Osilodrostat
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Endogenous Cushing's Syndrome
Treatment for Endogenous Cushing's Syndrome
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and…
- Trial name
- SONICS (NCT01838551)
- Testing
- Levoketoconazole
- Where
- 42 sites in United States, Belgium and 13 more
- Volunteers
- 94 people
- Sponsor
- Cortendo AB
Hypercortisolism
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with…
- Trial name
- GRADIENT (NCT04308590)
- Testing
- Relacorilant
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 137 people
- Sponsor
- Corcept Therapeutics
Cushing's Disease
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly…
- Trial name
- NCT00612066
- Testing
- rosiglitazone maleate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cushing's Disease
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
The purpose of this study was to confirm efficacy and safety of osilodrostat for the treatment of patients with Cushing's disease who are candidates for medical therapy.
- Trial name
- LINC-4 (NCT02697734)
- Testing
- osilodrostat
- Where
- 36 sites in United States, Belgium and 12 more
- Volunteers
- 73 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
- Trial name
- SEASCAPE (NCT01582061)
- Testing
- Pasireotide sub-cutaneous
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Cushing Disease
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma.
- Trial name
- NCT00171951
- Testing
- Pasireotide
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Endocrine Disease, Diabetes
Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults
Background: Metabolic syndrome is a name given to a group of factors that tend to occur together. These risk factors include central obesity (extra weight around the middle of the body) and high blood pressure and blood sugar…
- Trial name
- NCT01419535
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome, Endocrine Disease
New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome is an endocrine disorder causing an over production of the hormone cortisol. Cortisol is produced in the adrenal gland as a response to the production of corticotropin (ACTH) in the pituitary gland.
- Trial name
- NCT00001849
- Testing
- Pentetreotide, 18F-DOPA, CT scan
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing's Disease
Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
This study will evaluate the safety and efficacy of two different doses of Pasireotide in patients with de novo or recurrent/persistent Cushing's Disease.
- Trial name
- NCT00434148
- Testing
- Pasireotide
- Where
- 68 sites in United States, Argentina and 16 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion.
- Trial name
- NCT00422201
- Testing
- Mifepristone
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- HRA Pharma
Iatrogenic Cushing Disease
Prevention of Metabolic Complications of Glucocorticoid Excess
According to current estimates, nearly 1% of the general population is treated with long-term glucocorticoids. Chronic hypercortisolism leads to a phenotype that resembles the metabolic syndrome.
- Trial name
- NCT01319994
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Barts & The London NHS Trust
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Neoplasm, Pituitary Neoplasm
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
- Conditions
- Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
- Trial name
- NCT00958841
- Testing
- pasireotide LAR
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals